# A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome

**Authors:** Sara Anjum Niinuma, Haniya Habib, Ashleigh Suzu-Nishio Takemoto, Priya Das, Thozhukat Sathyapalan, Stephen L. Atkin, Alexandra E. Butler

PMC · DOI: 10.3390/cells14050377 · 2025-03-05

## TL;DR

This study explores differences in Ras signaling and growth factors in women with and without PCOS, finding altered levels of specific proteins that may be linked to PCOS pathophysiology.

## Contribution

The study identifies specific growth factors and receptors that differ in PCOS women, suggesting inherent biological features of the syndrome.

## Key findings

- EGF1, EGFR, and EGFRvIII were decreased in PCOS women.
- FGF8, FGF9, and FGF17 were increased in PCOS women.
- VEGF-D, IGF1, IGF-1sR, and PDGFRA were decreased in PCOS women.

## Abstract

Objective: Rat sarcoma (Ras) proteins, Kirsten, Harvey, and Neuroblastoma rat sarcoma viral oncogene homolog (KRAS, HRAS, and NRAS, respectively), are a family of GTPases, which are key regulators of cellular growth, differentiation, and apoptosis through signal transduction pathways modulated by growth factors that have been recognized to be dysregulated in PCOS. This study explores Ras signaling proteins and growth factor-related proteins in polycystic ovary syndrome (PCOS). Methods: In a well-validated PCOS database of 147 PCOS and 97 control women, plasma was batch analyzed using Somascan proteomic analysis for circulating KRas, Ras GTPase-activating protein-1 (RASA1), and 45 growth factor-related proteins. The cohort was subsequently stratified for BMI (body mass index), testosterone, and insulin resistance (HOMA-IR) for subset analysis. Results: Circulating KRas, and RASA1 did not differ between PCOS and control women (p > 0.05). EGF1, EGFR, and EGFRvIII were decreased in PCOS (p = 0.04, p = 0.04 and p < 0.001, respectively). FGF8, FGF9, and FGF17 were increased in PCOS (p = 0.02, p = 0.03 and p = 0.04, respectively), and FGFR1 was decreased in PCOS (p < 0.001). VEGF-D (p < 0.001), IGF1 (p < 0.001), IGF-1sR (p = 0.02), and PDGFRA (p < 0.001) were decreased in PCOS compared to controls. After stratifying for BMI ≤ 29.9 kg/m2, EGFR FGF8, FGFR1 VEGF-D, IGF1, and IGF-1sR differed (p < 0.05) though EGF1, EGFRvIII, FGF8, FGFR1, and VEGF-D no longer differed; after subsequently stratifying for HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed between groups (p < 0.05). Conclusions: Several growth factors that activate Ras differ between women with and without PCOS, and when stratified for BMI and HOMA-IR, only FGFR1, VEGF-D, IGF1, and IGF-1sR differed; these appear to be inherent features of the pathophysiology of PCOS.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], HRAS (HRas proto-oncogene, GTPase) [NCBI Gene 3265], NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893], RASA1 (RAS p21 protein activator 1) [NCBI Gene 5921], GFM1 (G elongation factor mitochondrial 1) [NCBI Gene 85476], EGFR (epidermal growth factor receptor) [NCBI Gene 1956], FGF8 (fibroblast growth factor 8) [NCBI Gene 2253], FGF9 (fibroblast growth factor 9) [NCBI Gene 2254], FGF17 (fibroblast growth factor 17) [NCBI Gene 8822], FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260], VEGFD (vascular endothelial growth factor D) [NCBI Gene 2277], IGF1 (insulin like growth factor 1) [NCBI Gene 3479], PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156]
- **Diseases:** Polycystic ovary syndrome (MONDO:0008487), PCOS (MONDO:0008487)

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, RASA1 (RAS p21 protein activator 1) [NCBI Gene 5921] {aka CM-AVM, CMAVM, CMAVM1, GAP, PKWS, RASA}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, VEGFD (vascular endothelial growth factor D) [NCBI Gene 2277] {aka FIGF, VEGF-D}, FGF17 (fibroblast growth factor 17) [NCBI Gene 8822] {aka FGF-13, FGF-17, HH20}, HRAS (HRas proto-oncogene, GTPase) [NCBI Gene 3265] {aka C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV}, FGF8 (fibroblast growth factor 8) [NCBI Gene 2253] {aka AIGF, FGF-8, HBGF-8, HH6, KAL6}, FGF9 (fibroblast growth factor 9) [NCBI Gene 2254] {aka FGF-9, GAF, HBFG-9, HBGF-9, SYNS3}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, GFM1 (G elongation factor mitochondrial 1) [NCBI Gene 85476] {aka COXPD1, EFG, EFG1, EFGM, EGF1, GFM}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}
- **Diseases:** PCOS (MESH:D011085), insulin resistance (MESH:D007333)
- **Chemicals:** testosterone (MESH:D013739)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11898917/full.md

---
Source: https://tomesphere.com/paper/PMC11898917